Ftse Mib
33.736,40
0,00%
DAX
17.905,58
0,00%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
59.340,12
0,37%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Verastem Inc (VSTM) Verastem Inc (VSTM) Notizie

Verastem Inc

VSTM
10,36
0,38 (3,81%)
03 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/4/202422:05BWVerastem Oncology Announces Appointment of John Hayslip,..
04/4/202413:30BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
18/3/202412:00BWGlobal Patient Survey Results Reveal Significant Negative..
14/3/202421:05BWVerastem Oncology Reports Fourth Quarter and Full Year 2023..
11/3/202422:07EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
11/3/202412:30BWVerastem Oncology Announces Multiple Oral Presentations at..
05/3/202423:27BWVerastem Oncology Receives Orphan Drug Designation from FDA..
05/3/202422:30BWVerastem Oncology Announces Preclinical Presentations for..
08/2/202422:22EDGAR2Form SC TO-I - Tender offer statement by Issuer
02/2/202415:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
29/1/202422:01EDGAR2Form 8-K - Current report
29/1/202413:00BWVerastem Oncology Outlines Key 2024 Strategic Priorities and..
19/1/202413:54EDGAR2Form 8-K - Current report
18/1/202422:00BWVerastem Oncology Granted Fast Track Designation for..
11/1/202413:00BWVerastem Oncology to Participate in the B. Riley Securities..
09/1/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:02EDGAR2Form 8-K - Current report
05/1/202413:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
28/12/202322:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202322:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202322:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202322:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202322:01EDGAR2Form DEF 14A - Other definitive proxy statements
18/12/202313:00BWVerastem Oncology Selects Oral KRAS G12D Inhibitor..
13/12/202313:00BWVerastem Oncology Announces Initiation of a Confirmatory..
08/12/202322:10EDGAR2Form PRE 14A - Other preliminary proxy statements
21/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
13/11/202313:00BWNew Healthcare Professional Component of Let’s Talk About..
08/11/202323:01EDGAR2Form S-3 - Registration statement under Securities Act of..
08/11/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:12BWVerastem Oncology Reports Third Quarter 2023 Financial..
07/11/202313:00BWFirst-Of-Its-Kind, Multi-National Patient Impact Survey..
06/11/202313:00BWVerastem Oncology Announces Efficacy and Safety Data of..
27/10/202322:41EDGAR2Form 8-K - Current report
26/10/202322:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/10/202322:05BWVerastem Oncology Strengthens Executive Leadership Team with..
18/10/202322:50BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
14/10/202318:30BWVerastem Oncology Announces Initial Results of RAMP 203..
10/10/202322:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202313:00BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
28/9/202320:27EDGAR2Form 8-K - Current report
28/9/202320:15BWVerastem Presents Avutometinib and Defactinib Combination..
25/9/202322:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202322:08EDGAR2Form 8-K - Current report
05/9/202313:00BWVerastem Oncology to Participate in Upcoming Investor..
28/8/202313:00BWVerastem Oncology Enters Discovery and Development..
08/8/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:05BWVerastem Oncology Reports Second Quarter 2023 Financial..
Apertura: 10,01 Min: 9,81 Max: 10,45
Chiusura: 9,98

La tua Cronologia

NASDAQ
VSTM
Verastem
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network